Avicanna shows improved absorption in Pwdrx studies

Executive Summary

• Avicanna Inc. announced positive preclinical data for its novel PwdRx powder drug delivery platform, which is designed to improve the bioavailability and absorption of highly lipophilic cannabinoids (CBD, CBG, THC, CBN).
• The company filed a provisional patent application with the USPTO covering the composition, methods of use, and utility of the PwdRx platform for treating pain and inflammation conditions.
• Preclinical studies indicate the PwdRx platform offers significantly enhanced pharmacokinetic profiles compared to conventional MCT oil-based formulations, including higher bioavailability, faster peak plasma levels, and higher peak concentrations.

Key Details

• Patent Filing: A provisional patent application was filed with the United States Patent and Trademark Office (USPTO).
• Patent Scope: Covers the composition, methods of use, and potential utility of the PwdRx platform in treating pain and inflammation, specifically including rheumatoid arthritis, osteoarthritis, neuropathic pain, fibromyalgia, migraine, and multiple sclerosis.
• Technology Platform: PwdRx is a novel powder drug delivery system designed to address formulation challenges such as poor water solubility, low/variable bioavailability, and delayed onset of action associated with lipophilic cannabinoids.
• Preclinical Pharmacokinetic Results (vs. MCT Oil):
  • Bioavailability (AUC): 74% higher.
  • Peak Plasma Levels (TMAX): 63% faster.
  • Peak Plasma Concentration (CMAX): 134% higher.
• Manufacturing & Formulation Capabilities: The technology supports scalable pharmaceutical production in solid-oral and powder-based formats, including tablets, capsules, sachets, and pouches.
• Product Features: Designed to offer long-term stability, manufacturing versatility, and tunable drug release capabilities to tailor product profiles to specific patient needs.
• Strategic Impact: The advancement strengthens Avicanna’s global intellectual property portfolio and aims to unlock new pharmaceutical and commercial product opportunities in the cannabinoid delivery space.

Notable Quotes

• "By improving dispersion, solubility and consistency of uptake, the PwdRx platform has the potential to enable health care providers greater flexibility to tailor potential treatment options for patients managing conditions associated with pain and inflammation." — Dr. Karolina Urban, Executive Vice-President, Medical and Scientific Affairs, Avicanna.
• "The advancement of our PwdRx platform represents another significant step forward in the science and technology of cannabinoid delivery and further strengthens our global intellectual property portfolio... We believe this novel technology will unlock potential new and different pharmaceutical and commercial product opportunities and further demonstrates Avicanna's leadership in advancing innovation in the science and technology of cannabinoids." — Aras Azadian, Chief Executive Officer, Avicanna.